Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator
April 27, 2026
[wp-rss-aggregator template=”xoma-releases-full” source=”374″ pagination=”on”]
- July 14, 2026XOMA Royalty Announces Closing of Its Acquisition by Ligand
- June 12, 2026XOMA Royalty Corporation Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record Date
- April 27, 2026Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator
- March 18, 2026XOMA Royalty Declares Quarterly Preferred Stock Dividends
- March 18, 2026XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements
- March 12, 2026XOMA Royalty to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026
- February 18, 2026XOMA Royalty to Present at Investor Conferences in March
- February 9, 2026XOMA Royalty Announces Closing of Tender Offer and Completed Acquisition of Generation Bio, Inc.
- January 12, 2026XOMA Royalty Announces CFO Transition
- December 30, 2025XOMA Royalty and Takeda Execute Strategic Royalty Sharing Transaction and Amend Existing Agreement for Mezagitamab